Ganitumab

BIOLOGICAL11 trials

Conditions

Advanced Solid TumorsCarcinoidColon CancerColorectal CancerEwing SarcomaEwing's Sarcoma RecurrentGastrointestinal CancerLocally Advanced

Phase 1

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

CompletedNCT00562380

AmgenLymphoma, Prostate Cancer, Sarcoma +2

Start: 2005-10-31End: 2010-06-30Target: 64Updated: 2013-07-18

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

CompletedNCT00788957

NantBioScience, Inc.Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer +2

Start: 2008-10-27End: 2010-07-23Updated: 2024-08-07

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

CompletedNCT01298401

Radiation Therapy Oncology GroupPancreatic Cancer

Start: 2012-02-29End: 2013-11-30Updated: 2015-11-17

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer

WithdrawnNCT01473303

Alliance for Clinical Trials in OncologyPancreatic Cancer

Start: 2012-08-31Updated: 2016-06-28

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

TerminatedNCT03041701

National Cancer Institute (NCI)Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Start: 2017-07-07End: 2021-10-16Updated: 2022-04-14

Phase 2

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

CompletedNCT00891930

NantBioScience, Inc.Metastatic Colorectal Cancer

Start: 2009-05-05End: 2013-07-22Updated: 2024-07-17

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

CompletedNCT01327612

AmgenAdvanced Solid Tumors, Carcinoid, Colorectal Cancer +6

Start: 2011-03-03End: 2020-02-05Updated: 2021-02-21

Palbociclib + Ganitumab In Ewing Sarcoma

TerminatedNCT04129151

Dana-Farber Cancer InstituteEwing Sarcoma, Ewing's Sarcoma Recurrent

Start: 2019-12-05End: 2022-12-15Updated: 2024-08-01

Phase 3

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active, not recruitingNCT02306161

National Cancer Institute (NCI)Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow +3

Start: 2014-12-12End: 2026-09-17Updated: 2026-04-03

Unknown Phase

Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

NCT03029481

Jonsson Comprehensive Cancer CenterEwing Sarcoma

Updated: 2019-03-28

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

RecruitingNCT04199026

M.D. Anderson Cancer CenterMetastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma

Start: 2025-02-25End: 2028-12-31Target: 20Updated: 2026-02-19

Clinical Cancer Research2023-07-0318 citations

Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.

Journal of Clinical Oncology2022-06-0110 citations

Results of a phase I trial of ganitumab plus dasatinib in patients with rhabdomyosarcoma (RMS).

Journal of Clinical Oncology2022-06-014 citations

Abstract CT195: A phase 2 clinical trial of palbociclib and ganitumab for relapsed/refractory Ewing sarcoma

Cancer Research2020-08-151 citations

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.

2018-01-0172 citations

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

Pediatric Blood & Cancer2016-06-3096 citations

DI-033 Clinical response of rilotumumab in solid tumours

2016-02-14

Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.

Journal of Clinical Oncology2015-01-203 citations

Exploratory <i>RAS</i> analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2015-01-20